July 30, 2013 (www.investorideas.com newswire) Surgical imaging has long been a challenge for surgeons. Until about four years ago, patients undergoing surgery needed to be scanned post-procedure to ensure that the surgery was successful. However, intraoperative computed tomography (iCT) procedures now provide surgeons with a way to ensure successful surgeries before the patient has even left the operating room.
According to Dr. Ali Bydon, Clinical Director of Spine Neurosurgery and Director of the Spinal Biomechanics & Surgical Laboratory at Johns Hopkins Bayview Medical Center, “That [technology] means fewer trips to the operating room by the patient, better quality surgery, greater accuracy in removal of tumors, better patient outcomes, and potentially less healthcare expenditures.” A video produced by the Johns Hopkins Bayview Medical Center explains how iCT helps with patient safety and surgeon accuracy.
One company making huge strides in the iCT arena is Winnipeg, Canada-based IMRIS Inc * (Nasdaq:IMRS). On July 22nd, they received FDA 510(k) clearance to market VISIUS iCT, a ceiling-mounted scanner. Unlike rail-mounted systems of the past, this ceiling-mounted alternative clears up floor space in the operating room. The VISIUS iCT surgical theater offers a 64-slice scanner with diagnostic quality imaging, along with a personalized dose management system. The iCT also has the longest scanner travel range currently available on the market. By minimizing the space used by the scanner, surgeons will be better able to move surgical equipment throughout the space. IMRS closed July 26th at $2.71, down $0.06, with a market cap of $140.56 million. Its 52-week trading range is $2.21 – $4.75.
Another company making waves in the medical imaging community is FONAR Corporation (Nasdaq:FONR), based in Melville, NY. FONAR bills itself as the “Inventor of MR Imaging” and has had recent success with its Upright Multi-Position MRI Scanner. The Upright scanner allows doctors to view patients in a weight-bearing position, which can be helpful in diagnosing spinal problems. FONAR founder Raymond V. Damadian, M.D., recently presented at the Medserena Upright Imaging Center in London. The company recently sold one of their Upright scanners to the Center, which opened on May 28th of this year. FONR closed July 26th at $5.86, down $0.07, with a market cap of $37.20. Its 52-week trading range is $3.02 – $7.94.
Nashua, NH-based iCAD Inc (Nasdaq:ICAD) provides imaging and workflow solutions for doctors looking to detect cancer earlier. Their Computer-Aided Detection (CAD) products include SecondLook. This CAD product will be a component of the PowerLook Advanced Mammogram Platform, built in partnership with FujiFilm’s Aspire HD Full-Field Digital Mammography System. The platform was recently approved by the FDA and helps doctors detect certain cancers. ICAD closed July 26th at $6.21, up $0.05, with a market cap of $67.29 million. Its 52-week trading range is $1.75 – $6.90.
Each of these small-cap companies continues to release progressive new technologies for imaging and diagnosing medical problems, either in advance of surgery or during the procedure. Those interested in healthcare investing may do well to keep an eye on these imaging technology companies.
* Denotes a client of Allen & Caron, publisher of this blog.
The About Small Cap blog covers breaking news on small cap stocks from around the world, delving deep into pressing issues both large and small that affect small caps. For example, we recently covered groundbreaking news about artificial heart technology in the small cap world. We write about things like natural gas drilling and interviews with notable personalities across a wide variety of industries, like Elemer Piros in the biotech sector
This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.